Nanologica has recruited Dr. PK Dutta as SVP Sales and Senior Advisor for the business area of chromatography. Dr. PK Dutta will focus on sales growth of Nanologica’s chromatography products primarily in the US.
To accelerate sales of chromatography products following the successful upscaling of Nanologica’s silica towards ton scale, Dr. Dutta has been recruited as SVP Sales and Senior Advisor. The position includes leading efforts and strategy for market growth in direct and indirect sales in North America.
” Having approved the products from our ton scale manufacturing facility at Sterling Pharma Solutions, we now want to build a world class technical sales team for market growth. Dr. Dutta has an unparalleled track record in identifying prospects and executing deals and partnerships. We are truly excited to welcome him aboard as a Nanologican”, says Andreas Bhagwani, CEO of Nanologica.
Dr. Dutta has more than 25 years’ global experience in the pharmaceutical and biotechnology industries, most recently as President for YMC Americas, where he led the chromatography business for North and South America. Before that, Dr. Dutta spent more than 16 years at AkzoNobel holding positions as Vice President, Director and Business Manager, where most notably he led the business development for growth of specialty chemicals (Silica/Kromasil and Pharmaceutical Salt/Sanal) in North America, India, and China.
Dr. Dutta’s appointment is effective immediately and is based in the US.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.